122 related articles for article (PubMed ID: 34382525)
1. Targeting the HIF-1α/Cav-1 Pathway with a Chicory Extract/Daidzein Combination Plays a Potential Role in Retarding Hepatocellular Carcinoma.
Zakaria S; Nawaya R; Abdel-Hamid NM; Eldomany RA; El-Shishtawy MM
Curr Cancer Drug Targets; 2021; 21(10):881-896. PubMed ID: 34382525
[TBL] [Abstract][Full Text] [Related]
2. Daidzein and Chicory Extract Arrest the Cell Cycle
Abdel-Hamid NM; Zakaria S; Nawaya RA; Eldomany RA; El-Shishtawy MM
Recent Pat Anticancer Drug Discov; 2022; 18(2):187-199. PubMed ID: 35319392
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target.
Lin D; Wu J
World J Gastroenterol; 2015 Nov; 21(42):12171-8. PubMed ID: 26576101
[TBL] [Abstract][Full Text] [Related]
4. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
5. PFKFB3/HIF-1α feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells.
Long Q; Zou X; Song Y; Duan Z; Liu L
Biochem Biophys Res Commun; 2019 Jun; 513(3):642-650. PubMed ID: 30981500
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
7. Combined Treatment of Tanshinone I and Epirubicin Revealed Enhanced Inhibition of Hepatocellular Carcinoma by Targeting PI3K/AKT/HIF-1α.
Zhao J; Lin E; Cai C; Zhang M; Li D; Cai S; Zeng G; Yin Z; Wang B; Li P; Hong X; Chen J; Zou B; Li J
Drug Des Devel Ther; 2022; 16():3197-3213. PubMed ID: 36158238
[TBL] [Abstract][Full Text] [Related]
8. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Liu LP; Ho RL; Chen GG; Lai PB
Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus increases the anti-cancer effect of Huai Er by regulating hypoxia inducible factor-1α-mediated glycolysis in hepatocellular carcinoma.
Zhou L; Zhao Y; Pan LC; Wang J; Shi XJ; Du GS; He Q
World J Gastroenterol; 2022 Aug; 28(32):4600-4619. PubMed ID: 36157928
[TBL] [Abstract][Full Text] [Related]
11. Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation.
Mu H; Yu G; Li H; Wang M; Cui Y; Zhang T; Song T; Liu C
Cell Oncol (Dordr); 2021 Oct; 44(5):1151-1166. PubMed ID: 34339013
[TBL] [Abstract][Full Text] [Related]
12. HIF-1α plays a role in the chemotactic migration of hepatocarcinoma cells through the modulation of CXCL6 expression.
Tian H; Huang P; Zhao Z; Tang W; Xia J
Cell Physiol Biochem; 2014; 34(5):1536-46. PubMed ID: 25323032
[TBL] [Abstract][Full Text] [Related]
13. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
14. Transarterial embolization combined with RNA interference targeting hypoxia-inducible factor-1α for hepatocellular carcinoma: a preliminary study of rat model.
Ni JY; Xu LF; Wang WD; Huang QS; Sun HL; Chen YT
J Cancer Res Clin Oncol; 2017 Feb; 143(2):199-207. PubMed ID: 27638772
[TBL] [Abstract][Full Text] [Related]
15. Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1α Expression.
Chen Y; Li H; Chen D; Jiang X; Wang W; Li D; Shan H
Dig Dis Sci; 2022 Aug; 67(8):3806-3816. PubMed ID: 34383201
[TBL] [Abstract][Full Text] [Related]
16. [Hypoxia-inducible factor-1α mediates and regulates angiogenesis-related factors expression in hepatocellular carcinoma].
Sun JY; Chen XY; Wang L; Ye WX; Shen SJ; Yang JL; Yao M; Yao DF
Zhonghua Gan Zang Bing Za Zhi; 2020 Nov; 28(11):942-948. PubMed ID: 33256280
[No Abstract] [Full Text] [Related]
17. Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination.
El Shorbagy S; abuTaleb F; Labib HA; Ebian H; Harb OA; Mohammed MS; Rashied HA; Elbana KA; Haggag R
J Gastrointest Cancer; 2021 Mar; 52(1):269-279. PubMed ID: 32212089
[TBL] [Abstract][Full Text] [Related]
18. The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo.
Xu H; Chen Y; Li Z; Zhang H; Liu J; Han J
Eur J Pharmacol; 2022 Sep; 930():175154. PubMed ID: 35868447
[TBL] [Abstract][Full Text] [Related]
19. Innovative challenge for the inhibition of hepatocellular carcinoma progression by combined targeting of HSP90 and STAT3/HIF-1α signaling.
Saber S; El-Fattah EEA; Abdelhamid AM; Mourad AAE; Hamouda MAM; Elrabat A; Zakaria S; Haleem AA; Mohamed SZ; Elgharabawy RM; Morsy NE; El Adle Khalaf N; Mohammed OA; El-Bahouty WB; Mostafa SA; Abdelhady R; Galal O; ElSaid ZH; Yahya G; Shata A; Youssef ME
Biomed Pharmacother; 2023 Feb; 158():114196. PubMed ID: 36916405
[TBL] [Abstract][Full Text] [Related]
20. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.
Moser C; Lang SA; Mori A; Hellerbrand C; Schlitt HJ; Geissler EK; Fogler WE; Stoeltzing O
BMC Cancer; 2008 Jul; 8():206. PubMed ID: 18651980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
